News | October 13, 2022
Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
